Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335... | NCT00808678 | Trialant
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
ClinicalTrials.gov ID
NCT00808678
Lead Sponsor
AstraZenecaINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
90Actual
Last Update Posted
Sep 28, 2012Estimated
Start Date
Dec 2008
Primary Completion Date
Jan 2009Actual
Brief Summary
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.